Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented smart safety syringe products to the healthcare industry [6] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Sharps has a manufacturing facility in Hungary that has undergone significant upgrades to support high-volume production [2][6] Recent Developments - Sharps has commenced shipments under three customer orders tied to previously announced purchase agreements, marking its first commercial deliveries and transition to revenue-generating operations [2] - The company will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET, providing an opportunity for investors to gain insights into its operations and future prospects [1][8] Investor Engagement - The Investor Summit is tailored for investors focused on small- and micro-cap stocks, offering insights from management teams of emerging companies [3][4] - Registration for the Investor Summit is available for free, allowing investors to participate and learn more about Sharps and other companies [5]

Core Insights - Sharps Technology, Inc. has initiated shipments of its SecureGard™ and SoloGard™ smart safety syringes, marking its transition to a commercial-stage, revenue-generating company [1][5] Group 1: Product Shipments and Agreements - The first commercial order of SoloGard was shipped under a $50 million supply agreement with a U.S.-based leader in IV flushing solutions, including customized 10mL SoloGard syringes [2] - The initial purchase order for SoloGard is valued at $400,000 and is part of a five-year contract to supply up to 500 million syringes [2] - A separate shipment of SecureGard smart safety syringes was delivered to a Hungarian vaccine provider under a $100,000 purchase order, reflecting growing global demand [3] - Additionally, 200,000 units of 1mL low dead space syringes were shipped to a Swiss provider for use in specialized injection pens, representing the first tranche of a 1-million-unit order [4] Group 2: Manufacturing and Operational Milestones - The manufacturing of SoloGard is supported by advanced molding and automation technologies, enabling Sharps to meet anticipated demand increases in the second half of 2025 [2] - Significant upgrades to the Hungary-based facility have been made to support high-volume, high-precision production, enhancing production capacity and quality [5] - The company is building inventory and expanding capacity to support current and future purchase commitments under long-term strategic agreements [5] Group 3: Company Vision and Future Outlook - The CEO of Sharps Technology emphasized that these initial shipments represent a key operational milestone and validate years of R&D and strategic planning [5] - The company aims to deepen relationships with partners and drive additional growth in the upcoming quarters [6]